Rigel Pharmaceuticals (RIGL) Net Margin (2010 - 2026)

Rigel Pharmaceuticals' Net Margin history runs 16 years deep, the most recent figure standing at 14.71% for Q1 2026.

• On a quarterly basis, Net Margin fell 675.0% year-over-year to 14.71% in Q1 2026; TTM through Mar 2026 was 121.51%, a 10320.0% increase from a year earlier, with the FY2025 full-year figure at 124.72%, up 11497.0% from the prior year.
• Net Margin eased to 14.71% in Q1 2026 per RIGL's latest filing, from 384.04% in the prior quarter.
• Across five years, Net Margin topped out at 384.04% in Q4 2025 and bottomed at 164.0% in Q1 2022.
• The 5-year median for Net Margin is 0.03% (2023), against an average of 8.68%.
• Across the five-year window, Net Margin tumbled 21275 bps in 2022 and jumped 35914 bps in 2025, its largest moves.
• Year by year, Net Margin stood at 2.73% in 2022, then slumped by 99 bps to 0.03% in 2023, then surged by 80918 bps to 24.9% in 2024, then soared by 1442 bps to 384.04% in 2025, then slumped by 96 bps to 14.71% in 2026.
• Per Business Quant, the three latest RIGL Net Margin figures stand at 14.71% (Q1 2026), 384.04% (Q4 2025), and 40.17% (Q3 2025).